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Author's Personal Copyrepresenting deformation of myofibers during sys-
tole, is more reproducible and has previously been
shown to provide superior risk prediction compared
with LVEF in patients with both symptomatic and
asymptomatic severe AS (3).
The rationale for aortic valve intervention in pa-
tients with moderate AS and LV dysfunction stems
from the high event rate in these patients. Our study
shows that patients with the highest risk for mortality
are those with more abnormal GLS. The TAVR UN-
LOAD (Transcatheter Aortic Valve Replacement to
Unload the Left Ventricle in Patients With Advanced
Heart Failure) study is a randomized study investi-
gating whether symptomatic patients with moderate
AS and LVEF <50% benefit from TAVR compared with
medical therapy (4). The hypothesis is that relieving
the excess afterload of moderate AS in patients with
LV impairment may alleviate symptoms and improve
prognosis. A hypothesis generated from our data is
that intervention may more likely benefit those pa-
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Radiation-Associated Aortic Stenosis
Undergoing Transcatheter Aortic
Valve ReplacementA Layer-Specific Strain Analysis StudyPatients with aortic stenosis (AS) and prior medias-
tinal radiotherapy (XRT) represent a challenging
group (1–3). The detrimental effects due to the pres-
sure overload associated with AS may be com-
pounded by the presence of radiation heart disease.
Echocardiographic speckle-tracking strain analysis
can reliably estimate left ventricular (LV) systolic
function and the subtle changes in LV performance
after transcatheter aortic valve replacement (TAVR)
(4). Because of the different vulnerability to pressure
overload of the 3 myocardial layers, multilayer strain
analysis can better characterize the extent of damage
in AS (3). No studies have assessed the effect of XRT
on myocardial function in patients with AS and
whether elimination of AS may lead to improvement
of LV systolic function. The aim of the present
retrospective study was to investigate the impact of
prior XRT on layer-specific strains and on post-TAVR
early outcomes and recovery of myocardial function
in patients with AS.
Of 227 patients with severe AS (aortic valve
area #0.6 cm2/m2) who underwent TAVR between
January 2013 and February 2018, 58 patients were
excluded because of suboptimal quality of speckle-
tracking image analysis, unclear radiation status,
nonsinus rhythm, or valve-in-valve TAVR. The study
was approved by the university hospital local ethics
committee of Liège, Belgium.
Of the remaining 169 patients (Society of Thoracic
Surgeons risk score 6.9  4.1%), 33 (20%) had histories
of XRT. All TAVR procedures were performed with
CoreValve self-expandable biologic prostheses (Med-
tronic, Minneapolis, Minnesota) via the transfemoral
(n ¼ 146) or transaxillary (n ¼ 23) approach. Clinical
endpoints were independently adjudicated according
to the Valve Academic Research Consortium-2
criteria. Post-TAVR echocardiographic assessment
was performed immediately before discharge and at
6  1.5 month follow-up.




































P = 0.0004 P = 0.0038 P = 0.014
(A) Rate of paravalvular regurgitation moderate or greater in patients with and those
without histories of radiotherapy (XRT). (B) Pre- and post–transcatheter aortic valve
replacement (TAVR) differences in layer-specific strains in patients with and those
without histories of XRT. AS ¼ aortic stenosis; EF ¼ ejection fraction; GLS ¼ global
longitudinal strain; LS ¼ longitudinal strain.
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Author's Personal CopyPatients with XRT did not differ from those with
lone AS in terms of clinical data (age, sex, cardio-
vascular risk factors, presence of cardiovascular dis-
ease, baseline brain natriuretic peptide level) and
baseline conventional echocardiography data (aortic
valve area and pressure gradients) except for mitral
calcifications (69% vs. 27%; p < 0.001) and stenosis
(greater than mild, 15% vs. 3.6%; p < 0.035). Five
patients (15%) in the XRT group presented with por-
celain aorta (p < 0.05). ST2 level was significantly
higher in patients with XRT (p ¼ 0.026). Conversely to
LV ejection fraction (LVEF) (53  11% vs. 56  11%;
p ¼ 0.26), longitudinal strains (LS) (epicardial LS 13.8
 4.2% vs. 12.2  4.04% [p ¼ 0.04], endocardial LS
18.04  5.5% vs. 15.8  4.9% [p ¼ 0.036], and global
LS 15.6  4.7% vs. 14.1  4.2% [p ¼ 0.07]) were
significantly decreased in patients with XRT. The
rates of stroke (1 [0.7%] vs. 3 [9%]; p ¼ 0.024) and
delirium (5 [3.7%] vs. 7 [21%]; p ¼ 0.0023) after TAVR
were higher in patients with XRT, whereas in-hospital
death (11 [8.1%] vs. 2 [6.1%]; p ¼ 0.51) and major
vascular complications (12 [8.9%] vs. 6 [18%];
p ¼ 0.11) were similarly distributed between groups.
The rate of paravalvular aortic regurgitation was also
higher in patients with histories of XRT after TAVR (15
[11%] vs. 9 [27%] for greater than moderate; p ¼ 0.016)
(Figure 1A). Follow-up echocardiography was per-
formed in 103 patients (30 of 33 [91%] of the XRT
group). At follow-up, post-TAVR LV systolic function
had improved significantly, with increases in LVEF,
transmural global LS, and epicardial and endocardial
LS (p < 0.05 for all). However, except for LVEF, the
rate of change was significant only in patients
without histories of XRT (DLVEF 3.3  4.6% vs.
2.3  2.9% [p ¼ 0.30], Dglobal LS 2.4  2.19% vs. 0.29
 3.5% [p ¼ 0.0004], Depicardial LS 2.4  2.1% vs.
0.73  3.7% [p ¼ 0.0038], and Dendocardial LS
2.16  2.5% vs. 0.44  4.3% [p ¼ 0.014]) (Figure 1B).
Patients with histories of chest radiation for cancer
and severe symptomatic AS have more marked
impairment of LV systolic function than those with
lone AS. Such alteration mainly concerns a decrease
in longitudinal function as assessed by layer-specific
strains and is underestimated by the study of LVEF.
After TAVR, recovery of heart function is better in
patients with lone AS. Conversely, in the presence of
radiation cardiomyopathy, myocardial recovery is
significantly impaired, with no post-procedural
improvement in LS. History of chest radiation is
associated with more paravalvular aortic regurgita-
tion and may increase the risk for neurologic events
during the hospital stay. A larger cohort of patients,
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Helps Reduce the Vulnerability of
Thin-Cap FibroatheromaAn ALTAIR Trial ReportLarge randomized controlled trials demonstrated that
adding anti–proprotein convertase subtilisin/kexin
type 9 (PCSK9) inhibitors to statins improved clinical
outcomes. Compared with statin monotherapy, the
use of PCSK9 inhibitors with statins significantly
reduced the incidence of acute myocardial infarction,
which can result from coronary plaque destabiliza-
tion. However, how vulnerable plaque is influenced
by more aggressive lipid-lowering therapy withPCSK9 inhibitors plus statins remains unclear.
Therefore, we designed the ALTAIR (Alirocumab for
Thin-Cap Fibroatheroma in Patients With Coronary
Artery Disease Estimated by Optical Coherence To-
mography) study to assess the effect of adding the
PCSK9 inhibitor alirocumab to rosuvastatin in pa-
tients with thin-cap fibroatheroma who underwent
coronary stent implantation.
ALTAIR is an open-label, prospective, randomized,
single-center study enrolling 24 patients (12 per
group) with low-density lipoprotein cholesterol
(LDL-C) levels >70 mg/dl despite statin treatment,
randomized to either the alirocumab group (alir-
ocumab 75 mg every 2 weeks and 10 mg/dl rosuvas-
tatin) or the standard-of-care group (10 mg/dl
rosuvastatin). The study protocol was approved by
the Institutional Review Board of Kobe University
Hospital. Optical coherence tomography (OCT) and
blood sample analyses (serum LDL-C, matrix metal-
loproteinase 9, high-sensitivity C-reactive protein,
interleukin-6, and vascular cell adhesion molecule–1
levels) were performed at baseline and at 36 weeks.
The primary endpoint was the increase in fibrous cap
thickness (FCT). Baseline and post-treatment OCT
was analyzed at an independent imaging core labo-
ratory (Kobe University Core Analysis Laboratory,
Kobe, Japan) blinded to treatment group allocation
(1). The fibrous cap was identified as a signal-rich
band overlying the lipid core. In each patient, the
minimum thickness of the fibrous-cap, defined as the
thickness of the signal-rich layer overlying the
lipid-rich plaque (2), was measured at the thinnest
part of the fibrous cap in 3 candidate frames selected
upon visual screening of all contiguous frames; the
smallest of the 3 values was retained.
Baseline characteristics and laboratory parameters
did not differ between the groups. Rosuvastatin and
alirocumab were not interrupted, and concomitant
use of ezetimibe or polyunsaturated fatty acids was
not started or altered during the study period. At
36 weeks, serum LDL-C levels were significantly
lower in the alirocumab group than in the standard-
of-care group (27 mg/dl [23 to 55 mg/dl] vs. 71 mg/dl
[64 to 77 mg/dl]; p < 0.0001), with a significantly
greater percentage change in the alirocumab group
(64.6% [71.2% to 60.2%] vs. 17.4% [28.7% to
1.6%]; p < 0.0001).The percentage change in matrix
metalloproteinase 9 was significantly greater in the
alirocumab group than in the standard-of-care group
(39.9% [50.2% to 11.0%] vs. 15.7% [26.6% to
30.0%]; p ¼ 0.024).
There was no difference between the groups
regarding findings on baseline OCT. Although FCT
